Management

ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership who proved their scientific excellence and financiers with deep understanding of pharma business.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

• Founder of Vonderscher&Co GmbH
• Senior executive with a broad R&D experience in the pharmaceutical industry
• Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
• Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
• Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
• Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
• Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
• Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
• Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)

Dr Pietro Scalfaro, MD, MBA, SVP Head of Clinical Development Chief Medical Officer

• In charge of strategy and operational management of the clinical drug programs
• Wide range experience in various roles in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
• Set up a Personalised Medicine Business Unit at Debiopharm Group and involved during start-up of eHealth and diagnostic companies (Biocartis, Sophia Genetics, Agendia, Immunexpress, Pryv, Orphanalytics)
• Practicing physician, with degrees from the University of Lausanne and the Swiss Medical Association in Paediatrics, Intensive Care and MBA

Dr Raphaël Darteil, PhD, SVP Head of non-clinical Development & Profiling

• Responsible for non-clinical development and in vitro / in vivo compound profiling
• More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
• Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
• COO and Member of the board at Genfit
• Various positions in the department of Gene Therapy of Aventis both in France and in the US
• Co-inventor of the patent protecting the use of Elafibranor (Phase III) for the treatment of NASH patients
• He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Keltoum Medji, MBA, VP Finance and Strategic Development

• Responsible for all finance activities including fundraising, investors relations, strategic partnerships
• More than 20 years’ experience in Orthopedic business supporting growth by an increased collaboration with supply chain & commercial organizations
• Strong experience in change management through diverse organizational changes as M&A, restructuring, reorganizations
• Graduated with a Master’s degree in Economics & Business Management and an MBA from EM Lyon Business School

Claudi Miquel, VP Legal Affairs & Board Secretary

• Responsible for all legal affairs and Secretary of the Board of Directors
• 15 years’ experience as an attorney as well as lead counsel for international organizations across different jurisdictions
• Experience in transactional, financing, IP, and corporate/governance matters
• Graduated with a master’s degree in business law from Vanderbilt University law school

Pete Leone, MBA, Head of Business Development & Licensing

• Responsible for Business development
• More than 30 years of C-level experience at public and private biopharmaceutical companies, with over $6 billion in upfront payments and potential milestones from business development transactions that he led to closure
• Various management roles at Arrowhead Pharmaceuticals (Nasdaq: ARWR), including business development, was CBO at Bicycle Therapeutics (Nasdaq: BCYC), and previously, a cofounder of three venture-backed companies, including Mersana Therapeutics (Nasdaq: MRSN)
• Corporate and not-for-profit board member, including SeromYx Systems, Third Monday Foundation, and Nuestros Pequeños Hermanos – NPH USA Northeast region
• Holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business

Thomas Hess, CPA & MBA, Chief Financial Officer

• Responsible for all financial and accounting activities
• 35 years of experience in financial and executive management including: 10 years of publice accounting at KPMG and 13 years with emerging and growth-stage life science companies
• Significant experience in public and private capital raising for healthcare companies
• Currently serving as a Consulting CFO for Danforth Advisors LLC
• Previously CFO of several healthcare companies including: Adolor (Nasdaq: ADLR), Yaupon Therapeutics and Genomind, Inc.
• Education: University of Pittsburgh (MBA) and Pennsylvania State University (BS in Accounting)

Founders of ENYO Pharma

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

• Founder of Vonderscher&Co GmbH
• Senior executive with a broad R&D experience in the pharmaceutical industry
• Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
• Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
• Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
• Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
• Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
• Board member of Inatherys, Step Pharma and ObsEva and SAB member of Inotrem SA
• Board member of LyonBiopôle and IMI-JU (Innovative Medicines Initiative-Joint Undertaking)

Laurène Meyniel-Schicklin, Engineer, co-founder and Head of Bioinformatics

• 15 years experience in omics data management and analysis for drug discovery Team and project leader, responsible for bioinformatics, scientific data management and analysis
• Engineer in Biology and Computer Science (Genopole, Evry)
• 20 publications, inventor on 3 patents
• Forbes: Top 50 Women in Tech 2018

Dr Benoît de Chassey, PhD, co-founder and Head of Drug Discovery Platform

• Responsible for the drug discovery plateform of ENYO Pharma
• 18 years experience in high-throughput approaches in drug discovery
• Former project leader in functional screenings at Aptanomics
• 23 publications, inventor on 14 patents

Pr Patrice André, MD, PhD, co-founder and Medical Advisor

• Professor Emeritus of Virology at Charles Mérieux Lyon Sud Medical School, Lyon 1 University
• Former Head of clinical virology department at the Hospices Civils de Lyon
• Former Team leader at the International Center for Infectiology Research, Inserm, CNRS, ENS Lyon
• > 200 publications in international peer review and high-impact journals, inventor on 7 patents
• Co-founder and President of Hormae Pharma

Dr Vincent Lotteau, PhD, co-founder and Scientific Advisor

• Inserm Research Director, Immunologist
• Team leader at the International Center for Infectiology Research
• Former director of Inserm Unit « Fundamental and clinical immunology »
• Participated to several governmental missions
• Post-doctoral fellow at Harvard University and Scripps Clinic Research Foundation
• > 100 publications, Inventor on 11 patents
• Co-founder of Hormae Pharma

Dr Jean-Jacques Garaud, MD, co-founder

• CEO of Inotrem SA from 2013 to 2021
• Executive vice-president Medical and Scientific Affairs, Inotrem SA
• A senior executive with a broad R&D experience in the pharmaceutical industry
• Most recently Executive VP Head of Pharma Research and Early Development at Roche (2010 to 2012)
• Executive VP Head of Development and Chief Medical Officer at Roche (2007 to 2010)
• Previously held other senior positions with Shering-Plough in the USA (1991 to 2001) and with Novartis in the USA and Switzerland (2001 to 2007)
• Known for his leading role in the development of Interferon alpha, ribavirin and PEG-interferon in hepatitis C virus in the 90s

Inserm Transfert Initiative, co-founder

• Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012.
• It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies’ development.
• Its current shareholders are BPI France, Inserm Transfert SA, AbbVie, Boehringer Ingelheim Venture Fund, GlaxoSmithKline, Ipsen, LFB, MSD (Merck & Co), Pfizer, Sanofi, SHAM, Shire.

www.it-initiative.fr